Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents;Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos

Actas Dermo-Sifiliograficas

Volumn 100, Issue 5, 2009, Pages 386-413

  Puig, L ^a   Carrascosa, J M ^b   Dauden E ^c   Sanchez Carazo J L ^d   Ferrandiz C ^b   Sanchez Regana M ^e   Garcia Bustinduy M ^f   Bordas, X ^g   Moreno, J C ^h   Hernanz, J M ⁱ   Laguarda, S ^j   Garcia Patos V ^k  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^j Hospital Casa de Salud Valencia   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

Adalimumab; Biologic agents; Biologic therapy; Efalizumab; Etanercept; Guidelines; Infliximab; Psoriasis; Treatment

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO;

DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; PSORIASIS VULGARIS; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; EVIDENCE-BASED MEDICINE; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 67650711365     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(09)70086-1     Document Type: Article

References (120)

1. C. Ferrándiz, X. Bordas, V. García-Patos, S. Puig, R. Pujol, and A. Smandia Prevalence of psoriasis in Spain (Epiderma Project: phase I) J Eur Acad Dermatol Venereol 15 2001 20 23 (Pubitemid 32842768)
2. L. Puig-Sanz La psoriasis, ¿una enfermedad sistémica? Actas Dermosifiliogr 98 2007 396 402
3. S.R. Rapp, S.R. Feldman, M.L. Exum, A.B. Fleischer Jr, and D.M. Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 3 Pt 1 1999 401 407 (Pubitemid 29418506)
4. D.D. Gladman, C. Antoni, P. Mease, D.O. Clegg, and P. Nash Psoriatic arthritis: epidemiology, clinical features, course, and outcome Ann Rheum Dis 64 Suppl 2 2005 ii14 ii17
5. J.M. Gelfand, D.D. Gladman, P.J. Mease, N. Smith, D.J. Margolis, and T. Nijsten Epidemiology of psoriatic arthritis in the population of the United States J Am Acad Dermatol 53 2005 573
6. P. Gisondi, G. Girolomoni, F. Sampogna, S. Tabolli, and D. Abeni Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis Eur J Dermatol 15 2005 279 283 (Pubitemid 41020858)
7. A.B. Gottlieb, P.J. Mease, J. Mark Jackson, D. Eisen, H. Amy Xia, and C. Asare Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices J Dermatolog Treat 17 2006 279 287 (Pubitemid 44595016)
8. A. García-Díez, C. Ferrándiz, F. Vanaclocha, L. Lizán, X. Badia, and G. Sellers What characterizes the severity of psoriasis? results from an epidemiological study of over 3,300 patients in the iberian region Dermatology 216 2008 137 151
9. J. Schmitt, and G. Wozel The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis Dermatology 210 2005 194 199 (Pubitemid 40529233)
10. A.Y. Finlay Current severe psoriasis and the Rule of Tens Br J Dermatol 152 2005 861 867 (Pubitemid 40704922)
11. D.M. Pariser, J. Bagel, J.M. Gelfand, N.J. Korman, C.T. Ritchlin, B.E. Strober National Psoriasis Foundation National Psoriasis Foundation clinical consensus on disease severity Arch Dermatol 143 2007 239 242 (Pubitemid 46294591)
12. C.E.M. Griffiths, C.M. Clark, R.J.G. Chalmers, A. Li Wan Po, and H.C. Williams A systematic review of treatments for severe psoriasis Health Technol Assess 4 2000 1 125
13. W. Sterry, J. Barker, W.-H. Boehncke, J.D. Bos, S. Chimenti, and E. Christophers Biological therapies in the systemic management of psoriasis: International Consensus Conference Br J Dermatol 151 Suppl 69 2004 3 17 (Pubitemid 39215184)
14. A. Nast, I. Kopp, M. Augustin, K.B. Banditt, W.H. Boehncke, and M. Follmann German evidence-based guidelines for the treatment of psoriasis vulgaris (short version) Arch Dermatol Res 299 2007 111 138 (Pubitemid 46835379)
15. L. Dubertret, U. Mrowietz, A. Ranki, P.C. van de Kerkhof, S. Chimenti, T. Lotti EUROPSO Patient Survey Group European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey Br J Dermatol 155 2006 729 736 (Pubitemid 44352553)
16. T. Nijsten, T. Rolstad, S.R. Feldman, and R.S. Stern Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options Arch Dermatol 141 2005 19 26 (Pubitemid 40144436)
17. H.L. Richards, D.G. Fortune, T.M. O'Sullivan, C.J. Main, and C.E. Griffiths Patients with psoriasis and their compliance with medication J Am Acad Dermatol 41 1999 581 583 (Pubitemid 29480408)
18. R.G. Langley, V. Ho, C. Lynde, K.A. Papp, Y. Poulin, and N. Shear Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches J Cutan Med Surg 9 Suppl 1 2006 18 25
19. C.H. Smith, A.V. Anstey, J.N. Barker, A.D. Burden, R.J. Chalmers, D. Chandler British Association of Dermatologists British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 Br J Dermatol 153 2005 486 497 (Pubitemid 41248202)
20. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850
21. A. Nast, I.B. Kopp, M. Augustin, K.B. Banditt, W.H. Boehncke, M. Follmann Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD) Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris J Dtsch Dermatol Ges 5 Suppl 3 2007 1 119 (Pubitemid 47033875)
22. N. Woolacott, N. Hawkins, A. Mason, A. Kainth, Z. Khadjesari, and Y.B. Vergel Etanercept and efalizumab for the treatment of psoriasis: a systematic review Health Technol Assess 10 2006 1 233 i-iv
23. K. Reich, R. Sinclair, G. Roberts, C.E. Griffiths, M. Tabberer, and J. Barker Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis Curr Med Res Opin 24 2008 1237 1254 (Pubitemid 351741556)
24. A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, and A. Menter Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Br J Dermatol 159 2008 274 285 (Pubitemid 352009861)
25. J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, and W. Kirch Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials Br J Dermatol 159 2008 513 526
26. Puig L, Bordas X, Carrascosa JM, Daudén E, Ferrándiz C, Hernanz JM, et al. Documento de consenso sobre evaluación y tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermosifiliogr. En prensa 2009.
27. M.P. Schön Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety Clin Dermatol 26 2008 509 514
28. Kragballe K, Bischof D, Papp K. 10 years of safety experience with efalizumab in psoriasis. Poster 3655, 21st World Congress of Dermatology, Buenos Aires, Argentina, September 30-October 5, 2007.
29. M. Lebwohl, S.K. Tyring, T.K. Hamilton, D. Toth, S. Glazer, N.H. Tawfik Efalizumab Study Group A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2003 2004 2013 (Pubitemid 37448923)
30. K.B. Gordon, K.A. Papp, T.K. Hamilton, P.A. Walicke, W. Dummer, N. Li Efalizumab Study Group Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial JAMA 290 2003 3073 3080 (Pubitemid 37548113)
31. A. Menter, K. Gordon, W. Carey, T. Hamilton, S. Glazer, and I. Caro Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis Arch Dermatol 141 2005 31 38 (Pubitemid 40144437)
32. C.L. Leonardi, K.A. Papp, K.B. Gordon, A. Menter, S.R. Feldman, I. Caro Efalizumab Study Group Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial J Am Acad Dermatol 52 3 Pt 1 2005 425 433
33. K.A. Papp, R. Bressinck, S. Fretzin, B. Goffe, S. Kempers, K.B. Gordon Efalizumab Study Group Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial Int J Dermatol 45 2006 605 614
34. L. Dubertret, W. Sterry, J.D. Bos, S. Chimenti, S. Shumack, C.G. Larsen CLEAR Multinational Study Group Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial Br J Dermatol 155 2006 170 8127
35. W. Sterry, G. Stingl, R.G. Langley, H. Zacharie, M. Lahfa, A. Giannetti CLEAR Multinational Study Group Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial J Dtsch Dermatol Ges 4 2006 947 956
36. A.B. Gottlieb, K.B. Gordon, M.G. Lebwohl, I. Caro, P.A. Walicke, N. Li Efalizumab Study Group Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis J Drugs Dermatol 3 2004 614 624
37. A. Gottlieb, T. Hamilton, I. Caro, P. Kwon, P. Compton, and C. Leonardi Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial J Am Acad Dermatol 54 2006 S154 S163
38. C. Leonardi, A. Menter, T. Hamilton, I. Caro, B. Xing, and A.B. Gottlieb Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis Br J Dermatol 158 2008 1107 1116
39. N. Selenko-Gebauer, F. Karlhofer, and G. Stingl Efalizumab in routine use: a clinical experience Br J Dermatol 156 Suppl 2 2007 1 6 (Pubitemid 46434867)
40. L. Clark, and M. Lebwohl The effect of weight on the efficacy of biologic therapy in patients with psoriasis J Am Acad Dermatol 58 2008 443 446
41. R. Varma, J.A. Cafardi, W. Cantrell, and C. Elmets Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label study Am J Clin Dermatol 9 2008 105 109 (Pubitemid 351280954)
42. A. Colsman, J.M. Carrascosa, C. Ferrándiz, and J.C. Simón Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab J Eur Acad Dermatol Venereol 22 2008 1131 1134
43. Ficha técnica de efalizumab. http://www.emea.europa.eu/humandocs/ PDFs/EPAR/raptiva/H-542-PI-es.pdf
44. C.L. Leonardi, D. Toth, J.C. Cather, R.G. Langley, W. Werther, and P. Compton A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis Dermatology 213 2006 204 214 (Pubitemid 44567830)
45. R.G.B. Langley, W.P. Carey, E.S. Rafal, S.K. Tyring, I. Caro, and X. Wang Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience Clin Ther 27 2005 1317 1328 (Pubitemid 41598367)
46. K.A. Papp, R. Bressinck, S. Fretzin, B. Goffe, S. Kempers, and K.B. Gordon Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial Int J Dermatol 45 2006 605 614
47. http://www.fda.gov/MedWatch/safety/2008/Raptiva-PI.pdf
48. S.D. Doherty, A. Van Voorhees, M.G. Lebwohl, N.J. Korman, M.S. Young, S. Hsu Nacional Psoriasis Foundation National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents J Am Acad Dermatol 59 2008 209 217
49. J.M. Carrascosa Estrategias para optimizar el tratamiento con efalizumab Actas Dermosifiliogr 99 Supl 1 2008 37 50 (Pubitemid 351239794)
50. J. Carrascosa, X. Soria, and C. Ferrándiz Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment J Eur Acad Dermatol Venereol 21 2007 828 829 (Pubitemid 46939062)
51. C. Ferrándiz, and J.M. Carrascosa Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute Br J Dermatol 156 Suppl 2 2007 24 29 (Pubitemid 46434871)
52. K.A. Papp, B. Millar, K.H. Gordon, I. Caro, P. Kwon, and P.G. Compton Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis J Am ACad Dermatol 54 2006 S164 S170
53. W. Carey, S. Glazer, A.B. Gottlieb, M. Lebwohl, C. Leonardi, and A. Menter Relapse, rebound, and psoriasis adverse events: an advisory group report J Am Acad Dermatol 54 2006 S171 S181
54. K.A. Papp, V. Ho, R. Langley, Ch. Lynde, Y. Poulin, and N. Shear Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis J Cutan Med Surg Suppl 1 2006 26 32
55. M. Viguier, P. Richette, F. Aubin, M. Beylot-Barry, M. Lahfa, and C. Bedane Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis Arthritis Rheum 58 2008 1796 1802 (Pubitemid 351847534)
56. K.A. Papp, I. Caro, H.M. Leung, M. Garovoy, and P.J. Mease Efalizumab for the treatment of psoriatic arthritis J Cutan Med Surg 11 2007 57 66
57. A.A. Saad, D.P. Symmons, P.R. Noyce, and D.M. Ashcroft Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials J Rheumatol 35 2008 883 890 (Pubitemid 351747132)
58. R. Goiriz, E. Daudén, S. Pérez-Gala, G. Guhl, and A. García-Díez Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers Clin Exp Dermatol 32 2007 176 179 (Pubitemid 46233024)
59. U. Wollina, G. Hansel, A. Koch, J. Schönlebe, E. Köstler, and G. Haroske Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients Am J Clin Dermatol 9 2008 1 14
60. D.E. Furst, R. Wallis, M. Broder, and D.O. Beenhouwer Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection Semin Arthritis Rheum 36 2006 159 167 (Pubitemid 44691882)
61. R. Mössner, M.P. Schön, and K. Reich Tumor necrosis factor antagonists in the therapy of psoriasis Clin Dermatol 26 2008 486 502
62. Ficha técnica de Enbrel. http://www.emea.europa.eu/humandocs/PDFs/ EPAR/Enbrel/H-262-PI-es.pdf
63. A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632 (Pubitemid 37523083)
64. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022 (Pubitemid 37448924)
65. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi Etanercept Psoriasis Study Group A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312 (Pubitemid 40933433)
66. P.C. van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, and A. Kaszuba Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension Br J Dermatol 159 2008 1177 1185
67. A. Moore, K.B. Gordon, S. Kang, A. Gottlieb, B. Freundlich, and H.A. Xia A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis J Am Acad Dermatol 56 2007 598 603 (Pubitemid 46400183)
68. K.B. Gordon, A.B. Gottlieb, C.L. Leonardi, B.E. Elewski, A. Wang, and A. Jahreis Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy J Dermatolog Treat 17 2006 9 17 (Pubitemid 43247302)
69. K. Gordon, N. Korman, and E. Frankel Efficacy of Etanercept in an integrated multistudy database of patients with psoriasis J Am Acad Dermatol 54 2006 S101 S111
70. S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726 (Pubitemid 46955730)
71. B. Elewski, C. Leonardi, A. Gottlieb, B. Strober, P. van de Kerkhof, and J.P. Ortonne Sustained long-term clinical efficacy and safety for up to 2.5 years of etanercept in patients with psoriasis. P2908 J Am Acad Dermatol 54 3 Suppl 2006 AB225
72. J.P. Ortonne, C.E.M. Griffiths, R. Strohal, C. Estojak, D. Robertson, and C. Molta Efficacy and safety of continuous versus intermittent etanercept in patients with moderate to severe psoriasis over 54 weeks: improved efficacy demonstrated in the CRYSTEL Study 5th EADV Spring Symposium Istanbul 2008 22-25 May
73. P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D.J. Burge Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 2000 385 390 (Pubitemid 30487495)
74. P. Mease Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with Etanercept Clin Exp Rheumatol 20 6 Suppl 28 2002 S116 S121
75. P. Mease, A. Kivitz, F. Burch, E. Siegel, S. Cohen, and P. Ory Etanercept treatment of psoriatic artritis Arthritis Rheum 50 2004 2264 2272
76. P. Mease, A. Kivitz, F. Burch, E. Siegel, S. Cohen, and P. Ory Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with Etanercept J Rheumatol 33 2006 712 721
77. A.S. Paller, E.C. Siegfried, R.G. Langley, A.B. Gottlieb, D. Pariser, I. Landells Etanercept Pediatric Psoriasis Study Group Etanercept treatment for children and adolescents with plaque psoriasis N Engl J Med 358 2008 241 251
78. C. Zachariae, N.J. Mørk, T. Reunala, H. Lorentzen, E. Falk, and S.L. Karvonen The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy Acta Derm Venereol 88 2008 495 501
79. R.J. Driessen, P.C. van de Kerkhof, and E.M. de Jong Etanercept combined with methotrexate for high-need psoriasis Br J Dermatol 159 2008 460 463 (Pubitemid 352009858)
80. L. Kircik, J. Bagel, N. Korman, A. Menter, C.A. Elmets, J. Koo Unite Study Group Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes J Drugs Dermatol 7 2008 245 253
81. A.B. Gottlieb, C.L. Leonardi, and B.S. Goffe Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database J Am Acad Dermatol 54 2006 S92 100
82. Datos del fabricante. Wyeth Pharma.
83. L. Naldi, A. Addis, S. Chimenti, A. Giannetti, M. Picardo, and C. Tomino Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare Project Dermatology 217 2008 365 373
84. P. Gisondi, C. Cotena, G. Tessari, and G. Girolomoni Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study J Eur Acad Dermatol Venereol 22 2008 341 344 (Pubitemid 351247425)
85. R. Saraceno, C. Schipani, A. Mazzotta, M. Esposito, L. Di Renzo, and A. De Lorenzo Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis Pharmacol Res 57 2008 290 295
86. J. Sieper, and J. Van Den Brande Diverse effects of infliximab and etanercept on T lymphocytes Semin Arthritis Rheum 34 5 Suppl 1 2005 23 27
87. S. Kruger-Krasagakis, V.K. Galanopoulos, L. Giannikaki, M. Stefanidou, and A.D. Tosca Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis Br J Dermatol 154 2006 460 466 (Pubitemid 43382653)
88. Ficha técnica de infliximab. http://www.emea.europa.eu/humandocs/ PDFs/EPAR/Remicade/H-240-PI-es.pdf.
89. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Lancet 357 2001 1842 1847 (Pubitemid 32539117)
90. A.B. Gottlieb, U. Chaudhari, L.D. Mulcahy, S. Li, L.T. Dooley, and D.G. Baker Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis J Am Acad Dermatol 48 2003 829 835 (Pubitemid 36706213)
91. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542 (Pubitemid 39278071)
92. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, C. Guzzo EXPRESS study investigators Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Lancet 366 2005 1367 1374 (Pubitemid 41443403)
93. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31.e1 31.e15
94. K. Reich, C. Griffiths, J. Barker, S. Chimenti, E. Daudén, and A. Giannetti Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus Dermatology 217 2008 268 275
95. U. Klotz, A. Teml, and M. Schwab Clinical pharmacokinetics and use of infliximab Clin Pharmacokinet 46 2007 645 660 (Pubitemid 47204851)
96. N. Cassano, A. Puglisi Guerra, C. Malara, F. Loconsole, A. Galluccio, and M. Pezza Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients Int J Immunopathol Pharmacol 20 2007 647 650 (Pubitemid 47531069)
97. P. Rutgeerts, G. van Assche, and S. Vermeire Review article: infliximab therapy for inflammatory bowel disease - seven years on Aliment Pharmacol Ther 23 2006 451 463 (Pubitemid 43381999)
98. P. Rich, C.E. Griffiths, K. Reich, F.O. Nestle, R.K. Scher, and S. Li Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year J Am Acad Dermatol 58 2008 224 231
99. P.S. Helliwell Therapies for dactylitis in psoriatic arthritis. A systematic review J Rheumatol 33 2006 1439 1441 (Pubitemid 44025166)
100. A. Cheifetz, and L. Mayer Monoclonal antibodies, immunogenicity, and associated infusion reactions Mt Sinai J Med 72 2005 250 256 (Pubitemid 41052052)
101. L.L. Lecluse, G. Piskin, J.R. Mekkes, J.D. Bos, and M.A. de Rie Review and expert opinion on prevention and treatment of infliximab-related infusion reactions Br J Dermatol 159 2008 527 536
102. L. Puig, E. Sáez, M.J. Lozano, X. Bordas, J.M. Carrascosa, and F. Gallardo Reacciones a la infusión de infliximab en pacientes dermatológicos Actas Dermosifiliogr 100 2009 103 112
103. S. Ehlers Tumor necrosis factor and its blockade in granulomatous infections:differential modes of action of infliximab and etanercept? Clin Infect Dis 41 Suppl 3 2005 S199 S203
104. L. Carmona, J.J. Gómez-Reino, V. Rodríguez-Valverde, D. Montero, E. Pascual-Gómez, E.M. Mola BIOBADASER Group Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 2005 1766 1772 (Pubitemid 40852885)
105. J.J. Gómez-Reino, L. Carmona, M. Ángel Descalzo Biobadaser Group Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection Arthritis Rheum 57 2007 756 761 (Pubitemid 46932080)
106. M.B. Carroll, and M.I. Bond Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection Semin Arthritis Rheum 38 2008 208 217
107. S. Vermeire, M. Noman, G. Van Assche, F. Baert, K. Van Steen, and N. Esters Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study Gastroenterology 125 2003 32 39 (Pubitemid 36799104)
108. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, et al. Anti-TNF therapy in RA and risk of malignant lymphomas. Relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis. 2008 May 8. doi:10.1136/ard.2007.085852.
109. T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2006 2275 2285 (Pubitemid 43736578)
110. J. Askling, C.M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, and N. Feltelius Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists Ann Rheum Dis 64 2005 1421 1426 (Pubitemid 41623851)
111. I. Nestorov Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34 5 Suppl 1 2005 12 18
112. Ficha técnica de Humira. http://www.emea.europa.eu/humandocs/PDFs/ EPAR/humira/H-481-PI-es.pdf.
113. A. Menter, S.K. Tyring, K.B. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115 (Pubitemid 350298146)
114. J.-H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.-P. Ortonne Efficacy and safety results from the comparative study of adalimumab (HUMIRA) versus methotrexate versus placebo in psoriasis patients (CHAMPION) Br J Dermatol 158 2008 558 566 (Pubitemid 351239154)
115. K.B. Gordon, R.G. Langley, C. Leonardi, D. Toth, M.A. Menter, and S. Kang Clinical response to adalimumab treatment in moderate to severe psoriasis patients: doubleblind, randomized clinical trial and open-label extension study J Am Acad Dermatol 55 2006 598 606 (Pubitemid 44436647)
116. K. Papp, C. Leonardi, K. Gordon, and M. Okun Efficacy and safety of adalimumab in a 120-week, open-label extension study in patients with moderate to severe chronic plaque psoriasis J Am Acad Dermatol 56 2 Suppl 2007 AB193
117. K. Gordon, S. Tyring, Y. Gu, and M. Okun P2654. Psoriasis patients treated continuously with adalimumab: Efficacy and safety results from months 12 to 18 J Am Acad Dermatol 58 2 Suppl 2 2008 AB129
118. Papp K, Parish LC, Gu Y, Goldblum O, Okun M. Efficacy outcomes for patients with psoriasis who interrupt adalimumab therapy. Poster FP1384. 17th Congress of the European Academy of Dermatology and Venereology. Paris, 17-20 September 2008.
119. M. Lebwohl, J. Bagel, J.M. Gelfand, D. Gladman, K.B. Gordon, and S. Hsu From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis J Am Acad Dermatol 58 2008 94 105 (Pubitemid 350302037)
120. R.G. Langley, and K.B. Gordon Duration of remission of biologic agents for chronic plaque psoriasis J Drugs Dermatol 6 2007 1205 1212